ACTION TO CONTROL CARDIOVASCULAR RISK IN DIABETES (ACCORD)

这个子项目是许多利用 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 雅阁是一项多中心研究，将招募10，000名患有2型糖尿病和高血压或高脂血症的患者，这些患者患有心血管（CV）疾病和/或>2个CV风险因素。受试者将被随机分配至标准（中位HbA 1c为7.5%）或强化（中位HbA 1c <6.0%）血糖控制组。此外，一项包含5800名受试者的2x2试验将评估贝特类药物治疗与他汀类药物治疗的联合应用。第二个2x2试验将评估4200例患者的强化（SBP<120 mmHg）与传统（SBP<140 mmHg）高血压治疗。受试者将接受4-8年随访，主要结局为首次发生重大CV事件，尤其是非致死性MI、非致死性卒中或CV死亡。还将评估糖尿病视网膜病变的发展或进展

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. ACCORD is a multi-center study that will enroll 10,000 individuals with type-2 diabetes mellitus and either hypertension or hyperlipidemia who have cardiovascular (CV) disease and/or >2 CV risk factors. Subjects will be randomized to either standard (median HbA1c of 7.5%) or intensive (median HbA1c<6.0%) glycemic control. In addition one 2x2 trial of 5800 participants will evaluate the addition of fibrate therapy to statin therapy. A second 2x2 trial of 4200 patients will evaluate intensive (SBP<120 mmHg) versus conventional (SBP<140mmHg) hypertension therapy. Subjects will be followed for 4-8 years, with the primary outcome being the first occurrence of a major CV event, especially non fatal MI, non fatal stroke or CV death. The development or progression of diabetic retinopathy will also be evaluated